Vitiligo - Macular Depigmentation, Tacrolimus
Conditions
Keywords
Vitiligo
Brief summary
Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed
Detailed description
Evaulation of efficacy and safety of narrowband uvb and tacrolimus and NBUVB and calcipotriol in patient if stable vitiligo with body surface area less than 20% It will be assessed by VASI score and VIisual analogie scale
Interventions
DRUGTacrolimus
Tacrolimus is calcineurin inhibitor that will act as immunomodulator
DRUGCalcipotriol
Calcipotriol is a vitamin D analogue that will act as immunomodulator
Sponsors
Dr ayesha wahid
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
\- Localized vitiligo Age 15 to 70years Body surface upto 20% Stable more than 3 months
Exclusion criteria
* • Pregnant or lactating female patients. * Skin malignancy or any other malignant skin condition. * Photo induced or photo aggravated dermatosis like (SLE, photodermatitis, rosacea, psoriasis, pemphigus vulgaris) along with vitiligo. * Prior history of allergy to tacrolimus or calcipotriol. * Other form of treatment for vitiligo within at least 1 month.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| VASI improvement upto 50% | 3 months | Improvement in VASI score upto 50% |
Countries
Pakistan
Outcome results
None listed